Personalized medicine in Europe: not yet personal enough?
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Personalized medicine has the potential to allow patients to receive drugs specific to their individual disease, and to increase the efficiency of the healthcare system. There is currently no comprehensive overview of personalized medicine, and this research aims to provide an overview of the concept and definition of personalized medicine in nine European countries. METHODS: A targeted literature review of selected health databases and grey literature was conducted to collate information regarding the definition, process, use, funding, impact and challenges associated with personalized medicine. In-depth qualitative interviews were carried out with experts with health technology assessment, clinical provisioning, payer, academic, economic and industry experience, and with patient organizations. RESULTS: We identified a wide range of definitions of personalized medicine, with most studies referring to the use of diagnostics and individual biological information such as genetics and biomarkers. Few studies mentioned patients' needs, beliefs, behaviour, values, wishes, utilities, environment and circumstances, and there was little evidence in the literature for formal incorporation of patient preferences into the evaluation of new medicines. Most interviewees described approaches to stratification and segmentation of patients based on genetic markers or diagnostics, and few mentioned health-related quality of life. CONCLUSIONS: The published literature on personalized medicine is predominantly focused on patient stratification according to individual biological information. Although these approaches are important, incorporation of environmental factors and patients' preferences in decision making is also needed. In future, personalized medicine should move from treating diseases to managing patients, taking into account all individual factors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Various studies reveal that the majority of professionals have a positive attitude towards PM in general or towards interventions, which are mentioned under the label of PM [27, 34, 43, 45, 47, 50, 79–83].”
From Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis (2021) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition to possible disparities in access to PM, professionals and patients fear discrimination based on the results of genetic testing [27, 79, 92, 97], particularly by insurance companies or employers [46, 51, 54, 63, 86, 94–96, 98, 115].”
From Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis (2021) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many clinicians and researchers are well aware of the limited [27, 30, 31, 35, 42, 79, 84] or ambiguous evidence [32] for the meaning of test results and possible treatment outcomes and regard the lack of practice guidelines as a barrier for the implementation of tests [27, 79].”
From Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis (2021) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Incidental findings [79, 96], variants of unknown significance [79] or results that indicate a high risk for an incurable disease can affect the well-being of patients [51].”
From Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis (2021) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For various reasons, professionals perceive communication on PM research, tests and therapies and obtaining informed consent as being increasingly complex [31, 79].”
From Patients’ and professionals’ views related to ethical issues in precision medicine: a mixed research synthesis (2021) · cites this paper as [79]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Hibbard, J. H., Stockard, J., Mahoney, E. R., & Tusler, M. (2004) · Health Services Research · doi:10.1111/j.1475-6773.2004.00269.x · Cited by 2,748
Miller, D. C., Sanda, M. G., Dunn, R. L., Montie, J. E., Pimentel, H., Sandler, H. M., McLaughlin, W. P., & Wei, J. T. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.116 · Cited by 383 · cited 1×
“For example, androgen-deprivation therapy is an option for the treatment of localized prostate cancer, but can cause impairment of urogenital function [51] as well as radical prostatectomy [52, 53].”
BackgroundWhat is personalized medicine: sharpening a vague term based on a systematic literature review
Schleidgen, S., Klingler, C., Bertram, T., Rogowski, W. H., & Marckmann, G. (2013) · BMC Medical Ethics · doi:10.1186/1472-6939-14-55 · Cited by 336 · cited 7×
“Although the findings of our survey were analysed in a qualitative way, they matched those obtained by Schleidgen and colleagues [3], who analysed the literature, categorized and quantified the results until they concluded that PM “seeks to improve stratification and timing of health care” by using biological informat…”
BackgroundResultInfluentialRosland, A.-M., Heisler, M., & Piette, J. D. (2012) · Journal of Behavioral Medicine · doi:10.1007/s10865-011-9354-4 · Cited by 322 · cited 1×
“Medication adherence and disease management can be affected by patients’ personal environment, and by behavioural factors, such as their knowledge, abilities, occupation, social status, cultural background and beliefs [49].”
BackgroundPotosky, A. L. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.6.430 · Cited by 195 · cited 1×
“For example, androgen-deprivation therapy is an option for the treatment of localized prostate cancer, but can cause impairment of urogenital function [51] as well as radical prostatectomy [52, 53].”
BackgroundFaulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A.-P., Hornberger, J., Hughes, D., Li, T., Malone, D., Payne, K., et al. (2012) · Value in Health · doi:10.1016/j.jval.2012.05.006 · Cited by 161
Self-citationFried, T. R., Tinetti, M. E., Towle, V. R., O’Leary, J. R., & Iannone, L. P. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.32 · Cited by 145 · cited 1×
“Patients may also have individual preferences for particular treatment modalities, the avoidance of certain side effects [50], and the benefit– harm trade-off of interventions, and may differ in the level”
BackgroundPersonalized Medicine in Breast Cancer: A Systematic Review
Cho, S.-H., Jeon, J., & Kim, S. I. (2012) · Journal of Breast Cancer · doi:10.4048/jbc.2012.15.3.265 · Cited by 122
Ciardiello, F., Arnold, D., Casali, P. G., Cervantes, A. M. R., Douillard, J.-Y., Eggermont, A. M. M., Eniu, A. E., McGregor, K., Peters, S., Piccart, M. J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu217 · Cited by 122 · cited 1×
“stances in their definitions of PM [5, 8, 15, 16, 26, 38, 41].”
Research works printed but not linked: 3
- Personalised medicine - opportunities and challenges for European healthcare. http://ec.europa.eu/research/health/pdf/13th-european-health-forum-workshop-report_en.pdf . Accessed 6 Jan 2015.
- Lenz C, Fensch M, Sollano JA. Implementing personalised medicine in clinical practice: Country investments and public-private partnerships in Europe. J für Pharmakologie und Therapie. 2012;21:3–7.
- Editorial N. Getting Personal - Targeted therapies work, but need help to fulfil their potential. Nature. 2011;473:253–4.
Cited by
Faulkner, E. C., Holtorf, A., Walton, S. M., Liu, C. Y., Lin, H., Biltaj, E., Brixner, D. I., Barr, C. E., Oberg, J. A., Sandhu, G., et al. (2020) · Value in Health · doi:10.1016/j.jval.2019.11.010 · Cited by 120
Self-citationErdmann, A., Rehmann-Sutter, C., & Bozzaro, C. (2021) · BMC Medical Ethics · doi:10.1186/s12910-021-00682-8 · Cited by 86
Hertz, D. L., Kidwell, K., Vangipuram, K., Li, F., Pai, M. P., Burness, M. L., Griggs, J. J., Schott, A. F., Poznak, C. H. V., Hayes, D. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0656 · Cited by 68
“In addition, our model can be used to estimate the target exposure associatedwith any risk of treatment-limiting peripheral neuropathy, perhaps to select appropriate thresholds for patients based on disease prognosis or individualized exposure targets for patients based on their personal preference of acceptable perip…”
MethodFast and accurate medication identification
Delgado, N. L., Usuyama, N., Hall, A. K., Hazen, R. J., Ma, M., Sahu, S., & Lundin, J. (2019) · npj Digital Medicine · doi:10.1038/s41746-019-0086-0 · Cited by 71
Huls, S. P. I., Whichello, C. L., van Exel, J. N. A., Groot, C. A. U., & de Bekker-Grob, E. W. (2019) · Value in Health · doi:10.1016/j.jval.2019.04.1930 · Cited by 53
Metadata
- Authors
- Di Paolo, A., Sarkozy, F., Ryll, B., & Siebert, U.
- Affiliations
- Uppsala University (SE)
- UMIT TIROL - Private University for Health Sciences and Health Technology (AT)
- Venue
- BMC Health Services Research
- Published
- 2017-04-19
- Volume
- 17
- Issue
- 1
- Pages
- 289-289
- ISSN
- 1472-6963 (ISSN-L)
- PMC
- PMC5395930
- OpenAlex
- W2607503467
- Cited by
- 54
- References
- 47
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 5 · 2021: 9 · 2020: 14 · 2019: 9 · 2018: 3 · 2017: 2
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- BMC Health Services Research (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Novartis
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Keywords
- personalized medicine, patient stratification, biomarkers, genetic testing, patient preferences, health technology assessment, patient segmentation, health-related quality of life, patient involvement in treatment decisions, Europe
- MeSH terms
- Decision Making, Europe, Forecasting, Humans, Interviews as Topic, Quality of Life, Technology Assessment, Biomedical, Patient Satisfaction, Patient Preference, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Personalized medicine in Europe: not yet personal enough? https://app.cochat.ai/papers/10.1186/s12913-017-2205-4
- The paper
- Di Paolo, A., Sarkozy, F., Ryll, B., & Siebert, U. (2017). Personalized medicine in Europe: not yet personal enough? BMC Health Services Research. https://doi.org/10.1186/s12913-017-2205-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.